Core Viewpoint - Jiangsu Qianshou Pharmaceutical Co., Ltd., a subsidiary of a well-known foreign pharmaceutical company, is involved in a scandal regarding the issuance of false invoices amounting to 309 million yuan [1][3]. Group 1: Invoice Fraud Details - From December 2019 to August 2021, Jiangsu Qianshou Pharmaceutical received 2,022 VAT invoices from 37 individual businesses, totaling 195 million yuan [1][3]. - Between November 2022 and October 2023, the company accepted 603 VAT invoices from 13 enterprises, amounting to 114 million yuan [2][3]. - The total amount of the fraudulent invoices is 309 million yuan [3]. Group 2: Administrative Penalties - The tax authority imposed a fine of 300,000 yuan on Jiangsu Qianshou Pharmaceutical for its involvement in the issuance of false invoices [1][4]. - The administrative penalty decision indicated that the company engaged in invoice exchanges without corresponding financial transactions, suggesting the acceptance of false invoices [4]. Group 3: Company Background - Jiangsu Qianshou Pharmaceutical was established in February 2018 and primarily engages in the wholesale and import-export of pharmaceuticals and medical devices [4]. - It is a wholly-owned subsidiary of Japan's Qianshou Pharmaceutical Co., Ltd., a well-known multinational company specializing in ophthalmic drug research and production since 1947 [4][5].

Group 1 - The company plans to distribute a cash dividend of 10 yuan per 10 shares and a capital reserve conversion of 4 shares for every 10 shares at the end of 2024, totaling a dividend payout of 175 million yuan [1] - The total dividend distribution for 2024, including the mid-year payout of 87.21 million yuan, amounts to 262 million yuan, representing 77.64% of the net profit attributable to shareholders [1] - The company has conducted a total of 9 year-end dividends and 4 mid-year dividends since its listing in 2016, with a cumulative dividend amount of 999.5 million yuan and an average dividend rate of 81.82% [5] Group 2 - The company specializes in the field of ophthalmic drugs, with 60 approved ophthalmic drug numbers, of which 38 are included in the medical insurance catalog and 6 in the national essential drug catalog [4] - In 2024, the company achieved significant growth, with operating revenue of 1.943 billion yuan, a year-on-year increase of 32.42%, and a net profit of 338 million yuan, a year-on-year increase of 40.84% [4] - The company’s net cash flow from operating activities reached 417 million yuan, reflecting a year-on-year growth of 31.31% [4]